Welcome to our dedicated page for Synergy Chc SEC filings (Ticker: SNYR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Synergy CHC Corp. (NASDAQ: SNYR) SEC filings page brings together the company’s official disclosures as a smaller reporting company in the consumer health and wellness sector. Synergy develops and markets branded products such as FOCUSfactor® brain-health supplements and functional beverages and Flat Tummy® women’s wellness offerings, and its regulatory filings provide detailed insight into how this business is structured and financed.
Through annual reports on Form 10‑K and quarterly reports on Form 10‑Q, Synergy reports product sales, license revenue, gross profit, operating expenses, operating income, net income, and non‑GAAP measures like EBITDA and Adjusted EBITDA. These filings also describe working capital, inventory levels, debt obligations, and stockholders’ equity or deficit, giving investors a view of how the company funds expansion of its FOCUSfactor® and Flat Tummy® brands.
Current reports on Form 8‑K document material events such as quarterly earnings releases, public offerings of common stock, changes to equity incentive plans, authorization of preferred stock, and board or executive changes. For example, Synergy has used Form 8‑K to report an underwritten public offering of common stock, amendments to its 2024 Equity Incentive Plan, authorization of preferred stock, and governance updates including director appointments and role transitions.
Registration statements such as the Form S‑1 provide additional background on the company’s business, risk factors, use of proceeds, capital structure, and status as a smaller reporting company. Investors interested in ownership changes and executive incentives can review equity plan amendments and related disclosures within these filings. On this page, AI-powered tools can help summarize lengthy documents, highlight key financial and governance changes, and make complex sections of 10‑K, 10‑Q, 8‑K, and S‑1 filings easier to understand.
Use this filings hub to track Synergy CHC Corp.’s official financial reporting, capital raises, governance actions, and other regulatory disclosures that shape the outlook for SNYR stock.
Synergy CHC Corp. is asking stockholders to approve several major items at its 2026 virtual annual meeting on June 29, 2026. Stockholders will vote on electing five directors and ratifying RBSM LLP as auditor for 2026.
They are also asked to approve an amendment to the 2024 Equity Incentive Plan to increase the share reserve to 150,000,000 common shares and allow repricing of outstanding awards, approve the full issuance of shares upon exercise of a Lender Warrant under Nasdaq Rules 5635(b) and 5635(d), and authorize one or more reverse stock splits at ratios up to 1‑for‑200. As of April 24, 2026, Synergy CHC had 14,899,883 common shares outstanding.
Synergy CHC Corp. director Kaushal Nitin received a stock-based compensation award of 306,433 restricted stock units on common stock. The award was reported as a grant or other acquisition with no cash price per share. According to the terms, each RSU represents a contingent right to one common share and the RSUs vested in full on the grant date. Following this grant, Nitin directly holds 306,433 common shares associated with this award.
Synergy CHC Corp. director Teresa Brigid Thompson received an equity award of 25,824 restricted stock units (RSUs). Each RSU represents a contingent right to receive one share of Synergy CHC common stock.
The RSUs were granted and fully vested on the grant date, with no cash exercise price. Following this award, Thompson holds 25,824 shares of common stock directly, reflecting a routine compensation-related grant under Synergy CHC’s 2024 Equity Incentive Plan.
Synergy CHC Corp. is soliciting proxies for its virtual 2026 Annual Meeting on June 29, 2026 to elect five directors, ratify RBSM LLP as auditors, approve an amendment to the 2024 Equity Incentive Plan to increase the share reserve to 35,000,000 shares and permit repricings, approve full issuance upon exercise of the Lender Warrant for Nasdaq compliance, and approve a reverse stock split of up to one-for-forty. The record date for voting is April 24, 2026, when 14,781,883 shares were outstanding. Management recommends a "FOR" vote on all proposals.
Synergy CHC Corp. files its annual report describing a consumer health, beauty, and lifestyle business built around two core brands: FOCUSfactor brain-health supplements and Flat Tummy weight-management products. The company sells mainly through major retailers like Costco, Amazon, Walmart, Walgreens, BJ’s and The Vitamin Shoppe, using an asset-light model with third-party manufacturers.
Management highlights growth plans in ready-to-drink energy and focus beverages, new SKUs, expanded advertising, digital engagement and international expansion into Canada, Mexico and planned entries into Asia and Australia. Key risks include high customer concentration, competition in fragmented nutraceutical markets, regulatory exposure, leverage, supply-chain dependence and identified material weaknesses in internal control over financial reporting.
Synergy CHC Corp. amended its term loan, changing repayment timing, interest mechanics, pricing, covenants and default terms, and issued a new lender warrant. The amended agreement schedules principal payments of $175,000 on each of July 1, 2026 and October 1, 2026, then $525,000 on January 1, 2027 and $350,000 quarterly from April 1, 2027. If the company does not raise at least $10,000,000 of equity by September 30, 2026, the loan margin increases by 2.00% per year until that target is met. Interest due on March 2, 2026 must be paid in kind, and the company can elect to pay all or part of the April 1, 2026 interest in kind. New financial tests include minimum Consolidated Adjusted EBITDA of $500,000 for the quarter ended June 30, 2026 and $1,000,000 for the quarter ended September 30, 2026, plus revised senior net leverage thresholds, initially up to 20.00:1.00 for the quarter ended December 31, 2025. Equity issuance proceeds must follow a new waterfall where the first $6,000,000 can be retained and the next $4,000,000 must repay the term loan, with additional prepayments on amounts above $10,000,000 depending on leverage. The amendment also temporarily forces loans onto a reference rate and restricts future Term SOFR elections until at least $4,000,000 of principal has been repaid. In connection with the amendment, the company issued a 10‑year warrant giving a lender the right to buy 3,000,000 common shares at $0.00001 per share, exercisable only after a defined event of default and capped at 19.9% ownership unless stockholders approve a higher level by June 30, 2026.
Synergy CHC Corp. reported that on February 27, 2026, Gravity Pharma General Trading LLC terminated, ab initio, a Brand License Agreement originally signed on March 31, 2025 and later amended on June 30, 2025. The agreement had granted Gravity an exclusive license to sell and market certain FOCUSfactor and Flat Tummy Co. products in the United Arab Emirates and Turkey in exchange for an aggregate license fee of $2.9 million, which the company had previously recorded as revenue. Despite the termination, Synergy CHC states that it continues to pursue registration and marketing of these products in the same territories.
Synergy CHC Corp. has filed a shelf registration statement that allows it to offer and sell up to $100 million of securities, including common stock, preferred stock, warrants, debt securities, subscription rights and units, in one or more future offerings. The filing also contemplates a sales agreement prospectus for common stock, with up to $5.69 million of shares available under that program inside the overall $100 million limit.
Synergy’s common stock trades on the Nasdaq Capital Market under the symbol SNYR; the last reported price on November 20, 2025 was $2.08 per share. As of that date, 11,251,853 shares of common stock were outstanding. The company plans to use any net proceeds for research and development, working capital, general corporate purposes, potential acquisitions and reducing indebtedness.
Synergy is a consumer health care, beauty and lifestyle products company built around two core brands, FOCUSfactor and Flat Tummy, sold through major retailers and online. Net revenue was $34.8 million for 2024, down 19% from 2023, and $24.3 million for the nine months ended September 30, 2025, down 1% year over year, with a new $2.9 million license agreement contributing to 2025 revenue.